ER/PR positive breast cancer are candidates for endocrine therapy regimens and Her2 positive breast cancer can be targeted with anti-Her2 therapies whereas ER/PR/Her2 negative or triple-negative breast cancer (TNBC) lack any targeted therapies [3]. The gene discussed is ESR1; the disease is triple-negative breast carcinoma.